• City View Green Holdings and Budd Hutt recently announced an agreement to acquire eight retail cannabis store locations in Alberta
• The potential economic impact of legalized adult-use cannabis in all its forms, along with transportation, licensing fees and security, is estimated at more than $22 billion in Canada
• City View’s focus is on growing high quality flower and creating premium edible offerings, distillates and water-soluble products

City View Green Holdings Inc. (CSE: CVGR), a vertically integrated cannabis company focused on seed to retail, is creating a diversified company that investors can appreciate. City View has successfully attracted top talent in a time when competition is fierce among firms looking to solidify their positions in the quickly growing cannabis marketplace.

Mike Hagopian, City View’s chief operations officer and “extraction guru,” is a case in point. He most recently served the same role at Dose Oil, a licensed processor of cannabis extracts in Seattle, Washington. Hagopian will help develop City View’s unique cannabis extract brands, as an article featuring the company states.

The company’s master grower/managing partner is Mario Meek, whose deep knowledge of the cannabis space includes 10 years of networking, growing and cultivation experience in the medical cannabis industry. Meek was an original founding partner of WeedMD and is experienced in every aspect of growing marijuana, from seed to the finished product.

Both men bring strong operational and creative forces to City View’s vision, which will soon be on display at the company’s facility in Brantford, Ontario. Plans to retrofit and buildout the 40,000 square foot space are underway, a news release states (http://ibn.fm/idarb). Importantly, City View has maintained its priority position in the licensing process with Health Canada, City View Green CEO Ian MacDonald confirmed in the release.

“With the recent changes announced to the application process, we believe timelines for inspection and approvals will be greatly improved and the value of a license will increase significantly,” MacDonald stated. “The new rules give priority to applicants like CVG with strong operational and financial resources. Our buildout at our Brantford facility will be completed in the coming months and we are confident our license will be granted shortly thereafter so we can begin operations and provide the finest flower and oils in the cannabis industry.”

City View also recently entered into an agreement to expand its brick-and-mortar footprint in the Canadian retail cannabis marketplace with Budd Hutt, the company’s retail arm that owns a 19.9 percent stake in City View, according to a news release (http://ibn.fm/38ROv). Budd Hutt plans to initially enter the Canadian retail cannabis marketplace through Alberta and intends to acquire eight pre-license retail cannabis store locations in the Alberta market. These stores have already obtained the appropriate regulatory approvals and are waiting on final approval from Alberta Gaming, Liquor and Cannabis (AGLC), which is expected before the end of 2019. The company plans to establish a flagship location in Alberta that will serve as a showpiece for the future of the proposed national retail chain.

For more information, visit the company’s website at www.CityViewGreen.ca

NOTE TO INVESTORS: The latest news and updates relating to CVGR are available in the company’s newsroom at http://ibn.fm/CVGR

• Direct Solar achieved more than $3 million in solar contracts in just 60 days
• SING has expanded into the commercial solar market, opening up additional revenue streams
• CEO shared news from multiple revenue streams on MoneyTV with Donald Baillargeon

SinglePoint Inc. (OTCQB: SING) is a well-diversified holding company. What started as a full-service, mobile-technology provider has grown into a recognized brand with multiple revenue streams. A recent acquisition in alternative energy has exceeded the company’s expectations, and growth is abundant across all of the company’s revenue streams.

Direct Solar, a subsidiary of SING, is a leading solar energy brokerage providing customers no upfront cost and the potential to save up to 50 percent off of their electricity bills. The company finds and installs the best available solar energy system for any residential or commercial building. In May 2019, SING acquired Direct Solar with the expectation of dramatically increasing revenues by more than $5 million in the first 12 months (http://ibn.fm/WISdE).

Direct Solar is currently on track to exceed those expectations, Contracting approximately $3.4 million in only two short months (http://ibn.fm/c975T). The company has found a unique niche in the solar market. As solar becomes more mainstream, SING and Direct Solar are optimistic about the future. Currently operational in eight states, Direct Solar has also begun to offer renewable energy options to larger-scale commercial projects.

This month, SING announced that Direct Solar signed its first funding agreement to supply small to medium commercial outfits with solar financing (http://ibn.fm/aRMr9). This gives Direct Solar the ability to supply the contractor for installation and finance the transaction for the business, all in one package, marking the first time that this financing option has been available to commercial operations of this size. “We have a pipeline of interested businesses that we now have the ability to finance,” Direct Solar CEO Pablo Diaz stated in a news release. “It is a completely untapped market in my opinion, with a high chance for major success.”

Diaz recently sat down with SING President Wil Ralston to explain the market opportunity and services that Direct Solar provides to both customers and contractors (http://ibn.fm/fJ0ZR). As Diaz mentioned, once customers see all that solar energy has to offer them economically, “solar sells itself.” This sentiment can be seen in Direct Solar’s incredible growth, generating $3.4 million in just 60 days. As more states discover the positive economic value of alternative energy, Direct Solar expects to continue to grow.

In a separate interview, SING CEO Greg Lambrecht joined Donald Baillargeon on MoneyTV (http://ibn.fm/lRDAM) to discuss growth across the company’s multiple revenue streams. The two discussed the exceptional growth of Direct Solar since its acquisition. The company is on track to bring in the $5 million that was anticipated in the first 12 months in only the first quarter. Lambrecht also shared news regarding SING’s investment in the CBD and hemp markets. He discussed a new product line called PURE Hemp Cigarette that contains zero nicotine and is all natural. SING is currently in discussion with the manufacturer of the product to become the only sales and marketing team to take PURE to market. The hemp cigarette is expected to be available at SingleSeed.com, but Lambrecht sees it being placed in traditional large retail vendors and convenience stores, as well.

In addition, SING is looking forward to continued growth across other revenue streams. “SING is undervalued, and in my opinion, it is headed in the right direction,” Lambrecht stated enthusiastically at the close of the interview. “So, go SING.”

SinglePoint specializes in acquisitions of small- to mid-sized companies, with an emphasis in new technologies, as well as providing investors with the opportunity to make investments across a wide range of assets, including payment processing, cannabis and renewable energies.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• California-based INmune Bio is developing therapies to battle cancers and Alzheimer’s disease by more effectively engaging the body’s own natural defenses
• Research published in a peer-reviewed scientific journal shows a mechanism by which scientists can track and strategize natural killer cell promotion as an innate physical response to cancer in lieu of other pharmaceutical inducements
• INmune Bio’s INKmune product, derived from the cell line used in its research, naturally targets “residual disease” cells that may survive other cancer treatments and revitalize themselves to create a relapse of cancer

The battle to marshal naturally occurring cells within the human body to destroy cancerous tumors has gained new intelligence that appears to strengthen an immunotherapy strategy employed by clinical-stage biotechnology company INmune Bio Inc. (NASDAQ: INMB). The encouraging report arises from research on tumor-primed vs. cytokine-primed human natural killer (NK) cells, published in June in peer-reviewed, open-access scientific journal PLOS ONE (http://ibn.fm/HuKXg).

“We are delighted to be sharing these data describing the unique molecular pathways triggered within human NK cells upon priming with INmune Bio’s own INB16 (INKmune) cell line,” INmune Bio co-founder and Chief Scientific Officer Dr. Mark Lowdell, who co-authored the study, stated in a news release announcing the publication (http://ibn.fm/LYvqj). “This work has combined expertise across many groups, and it was important to publish these data in a highly-regarded open access journal to ensure that they are available to the widest possible audience.”

INmune Bio is a clinical stage immuno-oncology company focused on successfully harnessing patients’ immune systems to treat cancer by targeting cells that may survive initial therapies and become resurgent to cause a relapse of the cancer. By controlling these “residual disease” cells, INmune Bio hopes to enable patients to live longer through a novel mechanism of action and a precision medicine approach that suppress or eliminate relapses.

The company’s INKmune drug is a biologic therapy that strives to activate the body’s innate immune system by “priming” NK cells that are at rest to go on alert, seek out and destroy cancerous cells. The therapy uses simple IV infusion of the INKmune cell line – a tumor cell product – to call up the NKs for duty.

The PLOS ONE report notes that the research comparing tumor cell activation to the results from increasingly popular work on cytokine-mediated activation (http://ibn.fm/A9UXg) shows that the two therapies demonstrate distinct effects and that tumor therapy has the potential to be more effective against cancer targets with potentially fewer side effects than the administration of cytokines such as IL-2 or IL-15.

The research paper identifies a unique signaling “fingerprint” expressed by NK cells after binding to CTV-1 tumor cells, which are the parent clones of INmune Bio’s INB16 cells. Scientists are then able to use data obtained from the “fingerprint” to build strategies for immunotherapy treatments.

Lowdell went on to state, “These data confirm that the primed NK cells generated by INB16 stimulation upregulate genes, which are crucial to NK-mediated killing of patients’ cancer cells, such as CD70 and CXCL10. These differences in gene expression may explain the greater cytotoxic activity of INB16 primed NK cells in vitro compared to cytokine primed cells which may lead to greater clinical efficacy.”

INmune Bio is also completing testing of its INB03 product, a checkpoint inhibitor that targets myeloid-derived suppressor cells (“MDSC”) that may produce a “shield” preventing a patient’s immune system from attacking cancer cells. The company is also exploring Alzheimer’s disease therapies using its XPro1595 product that targets the microglial immune cells of the brain, which may cause neuroinflammation that can kill nerve cells and promote synaptic dysfunction in the brain.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• Supreme’s Truverra acquisition is valued at approximately C$20 million
• Supreme Cannabis intends to repurpose Truverra’s Health Canada-licensed facility to produce cannabis extracts for use in concentrates and vaping liquids
• The company will gain entry into Europe through Truverra’s subsidiary

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) intends to acquire privately held, Toronto-based Truverra Inc. in a three-cornered amalgamation between Truverra, Supreme Cannabis and a wholly owned subsidiary of Supreme Cannabis. The transaction for 14.7 million common shares of Supreme Cannabis has a value of approximately C$20 million (http://ibn.fm/3Itkx).

Truverra’s Health Canada-licensed facility in Toronto, Ontario, will produce cannabis-derivative products for Legalization 2.0, an industry term for a second wave of regulations in Canada anticipated for fall 2019. Companies such as Supreme Cannabis are positioning themselves for this new growth opportunity (http://ibn.fm/vZVDR).

The transaction has been unanimously approved by the Supreme Cannabis and Truverra boards, as well as a special Supreme Cannabis committee. The closing is subject to Truverra receiving requisite approval from its shareholders at a special meeting. The transaction is expected to close prior to August 30, 2019 (http://ibn.fm/zRQJs).

Truverra is a private cannabis company that sells to Canada and the international cannabis markets through its subsidiaries, Truverra (Europe) B. V. and Canadian Clinical Cannabinoids Inc. (CCC). Truverra Europe, a wholly owned subsidiary based in the Netherlands, already sells a broad portfolio of hemp-based CBD products into European markets.

“With the acquisition of Truverra, we secure a Toronto-based facility equipped to extract our high-quality inputs for concentrates and vaping liquids in the near term,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “Truverra’s operations also provide an additional entry point into Europe’s CBD wellness market, where Truverra Europe has successfully launched multiple CBD products in various jurisdictions.”

Supreme Cannabis announced that it was planning to retrofit Truverra’s Health Canada-licensed, 5,000-square-foot facility in Ontario to produce both solvent and solvent-less concentrate and leverage its position as a cannabis producer with premium flower at scale.

The Truverra acquisition will also provide Supreme Cannabis with opportunities to address the international medical market. The announced agreement notes that Truverra would serve as Supreme Cannabis’ global medical brand, building on an existing R&D platform and established CBD offerings within Europe.

Supreme Cannabis is a Toronto-based company that is pursuing opportunities and generating sustainable growth in what it sees as a global emerging market. The company’s portfolio includes 7ACRES, an award-winning brand; Cambium Plant Sciences, a cultivation IP and plant-genetics company; Medigrow Lesotho, a Southern Africa cannabis oil producer; Supreme Heights, an investment platform focused on CBD; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://cnw.fm/FIRE

• China’s AR industry is estimated at RMB$55 billion in 2020
• Favorable Chinese government policies emphasize research and development of new technologies such as AR
• Few direct competitors in China create exceptional potential for AR application in educational materials and smart toys
• Total retail sales of toys and games in China soared to RMB$276.5 billion in 2017 with an annual growth rate of 19.9%
• Shift toward intelligent and interactive toys and games, along with rising disposable income in China, helped retail sales of electronic toys grow 24% while traditional toys grew at 7% in 2017
• Extensive portfolio of IR property with strong research and development teams and partnerships

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) is a cutting-edge creator, developer and operator of popular augmented reality (“AR”) interactive smart toys and educational games in China. Blue Hat’s mobile-connected entertainment platform connects physical items to mobile devices through wireless technologies, creating a unique interactive user experience in various mobile games, interactive educational materials and toys with mobile game features.

Blue Hat designs original toys and games that utilize augmented reality technology, motion capture technology, image recognition technology, voice control, light sense technology, infrared, levitation induction, and other trending scientific technologies to transverse the virtual with reality. Blue Hat creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. This combination provides users with a more natural form of human computer interaction, enhances a user’s perception of reality, and delivers a more immersive entertainment experience.

Proprietary Technology

Founded in 2010, Blue Hat’s proprietary technology, product research and development, marketing channels and brand operation are the cornerstones of the business. Blue Hat focuses on the combination of “online” and “offline” activity and the interaction between “entertainment” and “product” to create a high-tech entertainment platform combining mobile games and AR. With the help of computer graphics, motion capture technology, image recognition technology and visualization technologies, Blue Hat accurately “places” virtual objects into the physical world, creating a new and stimulating visual environment for users.

Blue Hat recently displayed a variety of its sci-tech products at the Guangzhou International Toy Exhibition in China including AR Racer, Elastic Bubbles, AR Space Track, AR Alloy Toy Car, AR Need a Spanking, 5D Animated Magic Aquarium, Bug Travelers, AR Picture Book and other interactive games and smart toys.

The company has multiple products in development including new generations of four primary product lines and two new product lines.

Patents and Copyrights

Blue Hat’s advanced AR technology in interactive entertainment is protected by 178 authorized patents with 44 patents in various stages of the application process.

Another 14 applications for Patent Cooperation Treaty, or PCT, have been filed for international patents. As of March 31, 2019, the company owns 645 copyrights for artwork, 71 registered trademarks and 27 software copyrights.

Sales and Marketing

There has been rapid growth in the toys and games industry in China over the last several years. Total retail sales of toys and games in China soared from RMB 111.8 billion in 2012 to RMB 276.5 billion in 2017 with an average annual growth rate of 19.9% in 2017. Blue Hat believes the company is well positioned with little competition as the toy industry rapidly shifts toward intelligent and interactive toys and games. Retail sales of electronic toys grew at 24% annually in 2017 while that of traditional toys grew at 7%.

In addition to a powerful ecommerce presence, Blue Hat has long-term relationships with partnered distributors that place the company’s AR interactive entertainment products into well-known international retail chains and retail outlets. Blue Hat’s integrated online and offline sales channels include e-commerce giants such as Amazon and Alibaba, retail chain stores and the company’s physical experience store located in Xiamen, China. Blue Hat plans to open or franchise approximately 100 additional stores in China by 2021.

Blue Hat’s community-based platform offers users a highly engaged and interactive community with online communication forums and offline social activities. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction. This novel educational experience helps realize optimal transformation of information, creating a knowledge and enhancing cognition.

Management

Director and CEO Xiaodong (Sean) Chen has over 20 years of experience creating, developing and producing toys and games related products. Chen earned his EMBA from Renmin University of China and has been chairman of the board of directors and general manager of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

CFO and Director Caifan, who has over 20 years of financial accounting and taxation experience, earned a degree in finance from Hunan University of Finance and Economics. He has served as director, deputy general manager and financial controller of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

Jianyong Cai, chief technology officer and director, has over 35 years of experience in data communication principles, communication network foundation, software engineering, communication network theory and technology and computer network architecture. He holds degrees in data communication principles, communication network foundation and software engineering from University of Science and Technology of China. He has been director, deputy general manager and chief engineer of Fujian Blue Hat Interactive Entertainment Technology Ltd. since January 2010.

For more information, visit the company’s website at www.BlueHatGroup.net

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

• The company’s new system focuses on the science behind unique combinations of THC and CBD
• The intent of the new system is to reduce consumer confusion related to cannabis products
• PLUS cannabis products were top sellers in California over the past 12 months

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), a manufacturer and marketer of cannabis food products, has rebranded its line of low-dosage, cannabis-infused edibles. The goal behind the new look is to ensure clarity and differentiation to its Uplift, Balance and Unwind lines for consumers (http://ibn.fm/sbdJU).

The new look includes three easy-to-understand banners and colors for the brand, which are designed to eliminate any confusion consumers have between the Uplift, Balance and Unwind cannabis edibles lines. PLUS cannabis edibles are available at more than 300 licensed retailers in California. In addition, PLUS edibles will be available at licensed retailers in Nevada by the end of the summer, the company said.

“Cannabis can be confusing,” PLUS CEO and co-founder Jake Heimark stated in a news release. “We hope our new system will help reduce some of that confusion. We worked with experienced market researchers to find out why people use cannabis, then translated those findings into an easy-to-use system of cannabis. We are excited to help our customers Uplift their experiences, bring Balance to their everyday and Unwind without getting unwound.”

PLUS has instituted a new look for this product line that offers a clear differentiation. The rebrand research was performed by Henry J. Rak Associates, and the new look was designed by agency Partners & Spade, the company said. The goal for the rebranding is to create the right mix of cannabinoids paired with a targeted flavor profile to give the customer an amazing product experience.

“We believe this system will make PLUS even more accessible to new consumers,” Heimark added. “And we hope our investments in consistency and quality will keep them coming back.” PLUS said that the new product and packaging system focuses on the science behind unique combinations of THC and CBD.

PLUS had the top two best-selling cannabis products in California over the past 12 months, in terms of units and retail dollars sold, according to the BDS Analytics’ GreenEdge Retail Sales Tracking Platform.

San Mateo, California-based PLUS is a cannabis-infused, branded products manufacturer selling to regulated medicinal and adult-use recreational markets in California and Nevada. PLUS is focused on building the largest cannabis brand by growing organically and through acquisitions.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• Record sales attributed to DVLP’s operational entity and subsidiaries
• CEO says that DVLP has built a diverse ecosystem of products and services and is creating a community of consumers and businesses in the cannabis space
• The company’s new 25,000-square-foot facility is expected to “exponentially amplify” its manufacturing capabilities

Golden Developing Solutions Inc. (OTC: DVLP) reported sales of $1,965,641 for Q2 2019, ended June 30. DVLP is an early-stage emerging company offering business services and/or products supporting the cannabis industry. The company’s portfolio includes several fully owned ancillary technology, CBD and cannabis businesses (http://ibn.fm/iUHZZ).

“We believe our diverse ecosystem of product and service offerings is creating a community of consumers and businesses,” DVLP CEO Stavros Triant stated in a news release. “It’s also successfully fulfilling needs across multiple channels of the cannabis and cannabis-related industries that weren’t previously available or developed.”

The company secured a new 25,000-square-foot facility in Denver, Colorado, in early June. DVLP expects (http://ibn.fm/mJwdZ) the facility to “exponentially amplify (its) manufacturing capacities in the future.” Triant added that, while the firm is increasing its manufacturing capability, it is also focused on building vertical management.

“We’ve built a technical foundation, and now we’re working to solidify a team to support it,” Triant added. “With leaders in varying verticals applying themselves across multiple brands, we’re not surprised to see the increased second-quarter sales figures.”

This multitiered strategy also drove the company’s recent acquisition of Infusionz LLC. This subsidiary offers online retail sales of cannabidiol (CBD), hemp oil, health and wellness-related products, and direct-to-retail wholesale products. These products include CBD-based tinctures, vapes, soft gels, traditional vitamins, supplements and more.

DVLP achieved fully reporting status through its filing of a Form 10 Registration Statement with the SEC, effective July 1. The filing ensures continued transparency with current and future investors. DVLP will file all detailed and audited financial statements, reports, policies and potential risk factors. It will also file a full 10K annual report for the year ended December 31, 2019 (http://ibn.fm/mWFbR).

For more information, visit the company’s website at www.GoldenDeveloping.com

NOTE TO INVESTORS: The latest news and updates relating to DVLP are available in the company’s newsroom at http://ibn.fm/DVLP

• Organigram’s proprietary nano-emulsion technology is expected to provide an initial onset of effects within 10 to 15 minutes for cannabis beverages
• The company’s shelf-stable, thermally stable, water-compatible and palatable cannabinoid nano-emulsion formulation allows for the production of both liquid and powdered beverage products
• Organigram plans to launch dried powder formulation beverage products in early 2020

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI), the parent company of leading licensed cannabis producer and cannabis-derived products manufacturer Organigram Inc., has developed a proprietary nano-emulsification technology. This new unique, fast-acting formulation will allow for the production of both powdered and liquid cannabinoid products. The development comes in the context of the much-anticipated legalization of adult recreational-use cannabis edibles in Canada and the ensuing boost in demand, as the company noted in a news release (http://ibn.fm/zy5Pt).

Organigram focuses on high-quality, indoor-grown cannabis for both medical patients and adult recreational users. Its proprietary technology allows for the development of products with a quick onset of the cannabinoid effect within 10 to 15 minutes. To determine the onset of the products, Organigram studied cannabinoid particles at a size of 20 nanometers. Organigram’s nano-emulsion technology is stable to temperature variations, mechanical disturbance, salinity, pH and sweeteners. Further testing is anticipated to occur in order to confirm the onset of action and the duration of the effect.

Previously, Organigram announced the launch of premium cannabinoid-infused chocolates. The company will also be working toward the release of additional dried powder formulation beverages in Canada in early 2020.

“This is an exciting time for cannabis product makers”, Organigram CEO Greg Engel said in a news release. “To ensure the satisfaction of adult consumers, companies have to deliver both predictability and reliability. Organigram’s technology and the powdered formulation put the customer in control, allowing them to infuse just about any beverage… This new method of delivery allows for a completely new experience.”

At the same time, Organigram is also actively seeking a partner with proven experience within the beverage market to take advantage of the liquid formulation it has developed.

On July 10, Organigram announced a collaboration with Lift & Co. Corp. (TSX.V: LIFT) (OTCQB: LFCOF), supporting the launch of Canada’s first branded cannabis educational program (http://ibn.fm/KEQiK).

The program, developed in partnership with MADD Canada, aims to promote the responsible sale of cannabis and will be available via the Lift & Co. CannSell retail training program. Currently, CannSell is the only mandatory, provincially approved cannabis training program for all Ontario retail workers. Organigram is the first licensed cannabis producer in Canada to partner up with Lift & Co. for the purpose of educational content creation.

The rollout of the branded Organigram module of the program started in June 2019. The module will deliver digital training on Organigram’s three-tiered growing methodology, as well as best practices.

“This module will allow Organigram to connect directly with budtenders at any time and educate retail staff about their product attributes, best practices and stay top-of-mind with budtenders – the only people in the value chain speaking directly with consumers,” Lift & Co CEO Matei Olaru added.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• Marijuana Company of America has begun accepting signups for its San Fernando Valley-based Viva Buds cannabis delivery venture as the official August launch draws near
• Viva Buds offers consumers the opportunity to not only receive cannabis products at a low market price but also to earn income from referring the service to others
• MCOA recently announced an LOI for a joint venture designed as a large farming operation for hemp-based CBD production, extractions and sales

Marijuana Company of America Inc. (OTCQB: MCOA) continues to build steam in its efforts to light up the enormous California cannabis market, announcing an expanded hempSMART product line and the prelaunch of signups for its premier cannabis distribution service and home cannabis business fostering strategy.

MCOA announced during the spring that it would partner with Natural Plant Extracts of California to form the joint venture Viva Buds, a Southern California tetrahydrocannabinol (THC)-based cannabis delivery service that will offer customers a line of high-quality products at low prices, with the added benefit of being able to build their own personal cannabis businesses if they wish (http://ibn.fm/tphFV).

More recently, MCOA announced plans to form an additional JV with Essence Farms LLC that will create the Riverside Hemp Project to grow, cultivate, manufacture, extract and sell legal hemp and hemp-derived cannabidiol (CBD) on a large California farming operation (http://ibn.fm/2h9tY).

The company’s hempSMART brand provides wellness industry consumers with full-spectrum, natural extracts designed to support the body’s endocannabinoid system in balancing cells and systems of the human body. The just-launched hempSMART Body Cream product is the latest addition to the lineup, formulated with 300mg of organically grown, full-spectrum, non-psychoactive CBD to replenish, restore and rejuvenate skin cells for improved elasticity, supple texture and healthy radiance (http://ibn.fm/8fPl9).

“The new hempSMART Body Cream is a major advancement in the wellness arena,” hempSMART Medical Advisory Board Chairwoman Paula Vetter stated in a news release. “The cream is completely free of toxins that are commonly found in many skin care products and absorbed through the skin and into the blood stream. Instead, hempSMART’s Body Cream is a topical wellness solution that sets a new standard in the industry by improving the overall health of skin with each use.”

The announcement states that the cream’s formulation is rich in omegas 3, 6, 7 and 9, along with naturally occurring plant ceramides to build a strong and vibrant cellular matrix deep within skin layers, and it includes botanicals such as organic aloe, sacha inchi oil, argan kernel oil, macadamia nut oil, rose hip seed oil, frankincense, tulsi, pomegranate seed oil, ashwagandha, turmeric oil, coconut oil and sea buckthorn oil.

The hempSMART brand was the key to driving the company’s 840 percent year-over-year increase in total revenues last year (http://ibn.fm/SD9Yf). Gross profits increased from a 47 percent gross margin to a 68 percent gross margin during the year, while the company’s net loss from operations dropped by 82 percent.

The company’s Viva Buds venture is getting on its feet in the San Fernando Valley, with a live virtual launch party anticipated for August 9 to mark the official commencement of its operations. The beginning of signups for its delivery service through its web portal allows customers the opportunity to make referrals prelaunch and use the “call your friend” approach to building their own businesses.

“We are excited to be a partner in what we believe will be a game changing and disruptive delivery model in the marketplace,” Natural Plant Extracts of California CEO Alan Tsai added. “We offer an incentivized program that is mutually beneficial for our customers as well as the company.”

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• ETST subsidiary CTI is engaged in the research and development of cannabidiol
• The company has partnered with Canna Inno Laboratories Inc. to strengthen its foothold in the Canadian CBD market
• ETST’s Earth Science Pharma is working to develop and bring to market medical devices and vaccines specifically designed for women

Earth Science Tech Inc. (OTCQB: ETST), headquartered in Doral, Florida, is an innovative biotech enterprise that offers CBD in the forms of vitamins, minerals, herbs, botanicals, personal-care products, homeopathies, functional foods and other products. Through its wholly owned subsidiaries, the company operates in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals, medical devices, and research and development.

ETST’s subsidiaries focus on developing roles as international leaders in the CBD arena:

• Cannabis Therapeutics Inc. (“CTI”) is an emerging biotechnology company that has ventured into the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and leverage the medicinal power of cannabidiol (http://ibn.fm/CDayh).
• Canna Inno Laboratories Inc. was formed by Earth Science Tech in 2017 as a strategic Montreal, Canada-based company to give ETST a foothold in Québec and provide the company with access to government grants, the first of which have just been approved (http://ibn.fm/jphlA).
• Earth Science Pharma Inc. is an emerging medical research company dedicated to developing leading-edge medical devices and vaccines that will improve the health of women around the world. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs such as chlamydia from a self-obtained gynecological specimen (http://ibn.fm/mAPZk).

In addition to the powerful global presence ETST’s subsidiaries are creating, ETST itself is working within the space. The company has partnered with the University of Central Oklahoma and DV Biologics Laboratory to work on projects that scientifically support and advance the health care benefits of its high-grade hemp CBD oil. Made using the supercritical CO2 liquid extraction process, ETST products deliver high purity, top quality full-spectrum cannabinoid oil (http://ibn.fm/XL1f6).

In addition, Earth Science Tech has agreements with CannaBiz and Desert Sun Distribution to distribute the company’s high-grade, full-spectrum cannabinoids line throughout pharmacies, chiropractors, dispensaries, athletic clubs and clinics in the United States (http://ibn.fm/R5wH5).

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST